LPS priming in early life decreases antigen uptake of dendritic cells via NO production

Galectin-3 Regulates Indoleamine-2,3-dioxygenase-Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis

Galectin-3 regulates numerous biological processes in the gut. We investigated molecular mechanisms responsible for the Galectin-3-dependent regulation of colon inflammation and evaluated whether Galectin-3 may be used as biomarker for monitoring the progression of ulcerative colitis (UC). The differences in disease progression between dextran sodium sulphate-treated wild type and Galectin-3-deficient mice were investigated and confirmed in clinical settings, in 65 patients suffering from mild, moderate, and severe colitis. During the induction phase of colitis, Galectin-3 promoted interleukin-1β-induced polarization of colonic macrophages towards inflammatory phenotype. In the recovery phase of colitis, Galectin-3 was required for the immunosuppressive function of regulatory dendritic cells (DCs). Regulatory DCs in Galectin-3:Toll-like receptor-4:Kynurenine-dependent manner promoted the expansion of colon-infiltrated T regulatory cells (Tregs) and suppressed Th1 and Th17 cell-driven colon inflammation. Concentration of Galectin-3 in serum and stool samples of UC patients negatively correlated with clinical, endoscopic, and histological parameters of colitis. The cutoff serum values of Galectin-3 that allowed the discrimination of mild from moderate and moderate from severe colitis were 954 pg/mL and 580 pg/mL, respectively. Fecal levels of Galectin-3 higher than 553.44 pg/mL indicated attenuation of UC. In summing up, Galectin-3 regulates the cross-talk between colon-infiltrating DCs and Tregs and represents a new biomarker for monitoring the progression of UC.

Protective Effect of Dexamethasone on Lipopolysaccharide-Induced Inhibition of Contractile Function of Isolated Lymphatic Vessels and Nodes

LPS has an inhibitory effect on contractile activity of bovine mesenteric lymphatic vessels and nodes and causes a pronounced decrease in the tone and phase contractions. The selective inhibitor of inducible NO synthase, 1400W, and cyclooxygenase-2 selective inhibitor, dynastat, significantly attenuated the inhibitory effect of LPS. Dexamethasone interferes with the inhibitory effect of LPS on bovine lymphatic vessels and nodes. It was concluded that LPS stimulates expression of inducible NO synthase and cyclooxygenase-2 in endothelial and smooth muscle cells of lymphatic vessels and nodes. Dexamethasone has a pronounced protective effect on the contractile function of lymphatic vessels and nodes affected by LPS and suppresses the expression of inducible NO synthase and cyclooxygenase-2.